🇺🇸 FDA
Pipeline program

PD-1inhibitor

SCR-ESCC-02

Phase 2 small_molecule active

Quick answer

PD-1inhibitor for Esophageal Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Shanghai Chest Hospital with 1 ClinicalTrials.gov record(s).

Program details

Company
Shanghai Chest Hospital
Indication
Esophageal Squamous Cell Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials